{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-031471","form_type":"8-K","ticker":"PAVM","cik":"0001624326","company_name":"PAVmed Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.847916+00:00","generated_at":"2026-05-31T09:43:46.008104+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PAVmed Q2 GAAP net loss $10.9M; Lucid EsoGuard test volume record 3,147 (up 31% QoQ)","bullets":["Q2 revenue $1.0M from EsoGuard test; GAAP net loss attributable to common $10.9M ($1.19/sh).","Adjusted non-GAAP loss $7.7M ($0.84/sh). Cash and equivalents $25.5M at June 30, 2024.","Lucid commercial EsoGuard tests: 3,147 in Q2 (single-quarter record), +31% sequential, +44% YoY.","Lucid held productive meeting with CMS MAC Palmetto GBA's MolDX program for EsoGuard coverage.","Veris launched pilot with Ohio State's James Cancer Hospital; actively pursuing independent financing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-031471","json":"https://secwatch.observer/filing/0001493152-24-031471.json","markdown":"https://secwatch.observer/filing/0001493152-24-031471.md","text":"https://secwatch.observer/filing/0001493152-24-031471.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1624326/000149315224031471/0001493152-24-031471-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1624326/000149315224031471/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:43:46.008104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}